Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer

Federico Pio Fabrizio, Angelo Sparaneo, Andrea Fontana, Tommaso Mazza, Paolo Graziano, Angela Pantalone, Paola Parente, Flavia Centra, Natalizia Orlando, Domenico Trombetta, Annamaria la Torre, Gian Maria Ferretti, Marco Taurchini, Concetta Martina Di Micco, Evaristo Maiello, Vito Michele Fazio, Antonio Rossi, Lucia Anna Muscarella

Research output: Contribution to journalArticle

Abstract

The silencing of SPARC (secreted protein acid and rich in cysteine) gene through methylation of its promoter region represents a common event in many solid tumors and it is frequently associated with tumor progression and an aggressive clinical outcome. Anyhow, the data concerning the epigenetic mechanism of SPARC deregulation and its prognostic value in lung cancer are still incomplete. We explored the aberrant methylation of SPARC and its effects in 4 non-small cell lung cancer (NSCLC) cell lines and 59 NSCLC tissues and correlated the methylation levels with clinical-pathological features and disease outcome of patients. In 3 out of 4 tumor cell lines high SPARC methylation levels were observed. An inverse correlation between the epigenetic silencing and SPARC expression was confirmed by 5-Aza-2'-deoxycytidine ((5-Aza-CdR) treatment that also significantly induced a reduction in cell viability, proliferation and tumor cell migration. In tissues, the DNA methylation levels of the SPARC gene were significantly lower in paired non-neoplastic lungs (NLs) and normal lungs distant from tumor (NLDTs) than in NSCLCs (p = 0.002 and p = 0.0034 respectively). A promoter hypermethylation was detected in 68% of squamous cell carcinoma (SqCCs, 17/25) and 56% of adenocarcinoma (ADCs, 19/34), with SqCC showing the highest levels of methylation. Higher SPARC methylation levels were significantly associated with higher mortality risk both in all NSCLCs early stage patients (Hazard Ratio, HR = 1.97; 95% Confidence Interval, CI: 1.32-2.93; p = 0.001) and in those with SqCC (HR = 2.96; 95% CI: 1.43-6.12; p = 0.003). Promoter methylation of SPARC gene should represent an interesting prognostic biomarker in NSCLC, with potential application in the squamous early-stage context. Further research in this setting on larger independent cohorts of lung patients with different histologies and stages of disease are warranted.

Original languageEnglish
JournalCells
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 22 2020

Keywords

  • early-stage
  • methylation
  • NSCLC
  • SPARC
  • squamous cell carcinoma

Fingerprint Dive into the research topics of 'Potential Prognostic Role of SPARC Methylation in Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this